@iScienceLuvr
Last week, Tempus AI acquired Paige for $81M. Paige was one of the first pathology AI companies, founded in 2017, and has the first FDA-approved pathology AI product. All in all, they've been trailblazers in the field. However, they only got acquired for $81M, despite raising a total of $241M. And the acquisition was clearly a pure data play (dataset of millions of pathology slides from Memorial Sloan Kettering Cancer Center). I think it's clear AI will have huge impact in pathology but it seems like companies like Paige may have been too early to directly capture the value?